Ipratropium bromide/salbutamol propellant-free inhalation - Boehringer Ingelheim

Drug Profile

Ipratropium bromide/salbutamol propellant-free inhalation - Boehringer Ingelheim

Alternative Names: Albuterol/ipratropium bromide propellant-free inhalation - Boehringer Ingelheim; Combivent Respimat; Combivent® propellant-free inhalation; Ipratropium bromide monohydrate/salbutamol sulfate - Boehringer Ingelheim; Ipratropium bromide/albuterol propellant-free inhalation - Boehringer Ingelheim; Salbutamol sulfate/ipratropium bromide monohydrate - Boehringer Ingelheim

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antiasthmatics; Antibronchitics; Atropine derivatives; Bronchodilators
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 06 Sep 2017 No recent reports on development identified - Phase-III for Chronic obstructive pulmonary disease in United Kingdom, Ukraine, Turkey, Taiwan, South Africa, Russia, Poland, New Zealand, South Korea, Greece, France and Argentina (Inhalation)
  • 28 Jul 2017 Chemical structure information added
  • 30 Mar 2015 Adverse events data from a phase III trial in Chronic obstructive pulmonary disease released by Boehringer Ingelheim
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top